Since 2010, significant progress has been made in the treatment of metastatic castrate resistant prostate cancer (mCRPC). While these advancements have improved survival, mCRPC remains a lethal disease, with a precision medicine framework that is lagging behind compared to other cancers. Poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) studies in prostate cancer (PCa) have focused primarily on the homologous recombination repair (HRR) genes, specifically BRCA1 and BRCA2. While homologous recombination deficiency (HRD) can be prompted by germline or somatic BRCA1/2 genetic mutations, it can also exist in tumors with intact BRCA1/BRCA2 genes. While the sensitivity of PARPi in tumors with non-BRCA DNA damage signatures is not as well established, it has been suggested that genomic alterations in DNA damage repair (DDR) genes other than BRCA may confer synthetic lethality with PARPI in mCRPC. The aim of this review is to summarize the literature on PARPi and their activity treating BRCA and non BRCA tumors with DNA damage signatures.
Cancers. 2022 Sep 29*** epublish ***
Ciara S McNevin, Karen Cadoo, Anne-Marie Baird, Stephen P Finn, Ray McDermott
Department of Histopathology and Morbid Anatomy, Trinity Translational Medicine Institute, Trinity College Dublin, D08 W9RT Dublin, Ireland., Department of Medical Oncology, St. James's Hospital, D08 NHY1 Dublin, Ireland., School of Medicine, Trinity Translational Medicine Institute, St. James's Hospital, D08 W9RT Dublin, Ireland., Department of Medical Oncology, Tallaght University Hospital, D24 NR0A Dublin, Ireland.